The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIlika Plc Regulatory News (IKA)

Share Price Information for Ilika Plc (IKA)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 28.00
Bid: 27.00
Ask: 29.00
Change: 0.00 (0.00%)
Spread: 2.00 (7.407%)
Open: 28.00
High: 28.00
Low: 28.00
Prev. Close: 28.00
IKA Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Joint Development agreement with Energizer

2 Feb 2012 07:00

RNS Number : 6494W
Ilika plc
02 February 2012
 



Ilika plc

("Ilika" or the "Company")

 

Joint Development agreement with Energizer

 

Ilika plc (AIM: IKA), the advanced cleantech materials discovery company, announces that it has entered into a joint development agreement with Energizer Battery Manufacturing Inc., in the USA, a world leading primary battery manufacturer, for the development of advanced materials.

 

Commenting on the contract, Graeme Purdy, CEO of Ilika, said: "We are delighted to have entered into this new commercial relationship with Energizer and become part of its global innovation network. Energizer has a clear vision for its next generation of products and well defined channels to market."

 

An Energizer spokesperson said: "Ilika's high throughput techniques are well-matched to our material development requirements and we look forward to rapid innovation in this collaboration."

 

For more information contact:

 

Ilika plc

www.ilika.com

Graeme Purdy, Chief Executive

Tel: 023 8011 1400

Steve Boydell, Finance Director

 

 

 

Nomura Code Securities Limited (NOMAD)

Tel: 020 7776 1200

Phil Walker / Christopher Golden

 

 

 

Walbrook PR Ltd

Tel: 020 7933 8780

Paul McManus

Mob: 07980 541 893 or paul.mcmanus@walbrookpr.com

Paul Cornelius

Mob: 07827 879 460 or paul.cornelius@walbrookir.com

 

 

ABOUT ILIKA

 

Ilika is an advanced materials company which accelerates the discovery of new and patentable materials using its unique high throughput technologies (''HTT'') process for identified end uses in the energy, electronics and biomedical sectors. This process enables hundreds of scalable materials to be made in a single, automated operation and subsequently tested for key properties.

 

Traditionally, materials development has been a slow and arduous task, with manual, sequential methods used to make samples of material that are then tested for suitability. On average, it takes between 7 and 10 years to move from an initial discovery through to the first commercial prototype. Experiments carried out by the Company can be executed 10 to 100 times faster than using traditional techniques.

 

The Company focuses on three principal sectors and has a number of active development programmes addressing markets within each sector:

 

Energy - developing innovative new materials for Lithium-ion batteries for vehicles for Toyota; developing high capacity hydrogen storage materials with Shell Hydrogen and Johnson Matthey through joint development programmes; developing cheaper alternatives to Platinum electrodes for use in fuel cells through a grant-funded project with the Carbon Trust; developing new materials for use in fuel cells for the transport sector for a major vehicle manufacturer; and carrying out in-house research on film photovoltaic solar cells.

 

Electronics - developing lead-free piezoelectric materials through a joint development programme with CeramTec; developing phase change memory materials for high capacity memory chips and high-performing electronic materials for a multi-national manufacturer.

 

Biomedical - developing polymers to enable the filtering of somatic stem cells from blood with a major global supplier of filters; it has been selling its Cryoskin and Myskin products for the treatment of burns and wounds in the UK through a specialist distributor and intends to commence clinical trials of its corneal bandage candidate.

 

The Group's commercialisation strategy is to enter into joint development or licensing agreements with large multinational companies which are seeking to commercialise products developed using the intellectual property created through jointly-funded programmes. Current commercialisation partners include large multinational companies such as Toyota, Shell, Johnson Matthey and CeramTec. The Company generates revenues from three sources: licensing and milestone payments from joint development programmes; fee for service from contract research projects; and from sales of Cryoskin and Myskin.

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
AGRUASKRUBAURAR
Date   Source Headline
14th Aug 20203:56 pmRNSHolding(s) in Company
14th Aug 20202:06 pmRNSSecond Price Monitoring Extn
14th Aug 20202:01 pmRNSPrice Monitoring Extension
24th Jul 20202:06 pmRNSSecond Price Monitoring Extn
24th Jul 20202:01 pmRNSPrice Monitoring Extension
17th Jul 20202:06 pmRNSSecond Price Monitoring Extn
17th Jul 20202:00 pmRNSPrice Monitoring Extension
17th Jul 202011:06 amRNSSecond Price Monitoring Extn
17th Jul 202011:02 amRNSPrice Monitoring Extension
15th Jul 20204:42 pmRNSSecond Price Monitoring Extn
15th Jul 20204:37 pmRNSPrice Monitoring Extension
9th Jul 20207:00 amRNSFinal Results
16th Jun 20207:00 amRNSCOVID-19 Update, Facility Re-opening
10th Jun 20204:14 pmRNSHolding(s) in Company
10th Jun 202011:05 amRNSSecond Price Monitoring Extn
10th Jun 202011:00 amRNSPrice Monitoring Extension
9th Jun 20207:00 amRNSTrading Update & Notice of Results
8th Jun 20204:42 pmRNSSecond Price Monitoring Extn
8th Jun 20204:36 pmRNSPrice Monitoring Extension
20th Apr 20207:00 amRNSAppointment of Non-Executive Director
20th Apr 20207:00 amRNSCEO appointed as NED of Bacanora Lithium plc
6th Apr 20207:00 amRNSInvestor presentation
30th Mar 20204:25 pmRNSHolding(s) in Company
30th Mar 20202:40 pmRNSHolding(s) in Company
27th Mar 20205:26 pmRNSHolding(s) in Company
27th Mar 202010:58 amRNSHolding(s) in Company
27th Mar 20209:00 amRNSAward of Share Options, Exercise of Options & TVR
25th Mar 20201:45 pmRNSResults of General Meeting and Open Offer & TVR
25th Mar 202011:06 amRNSSecond Price Monitoring Extn
25th Mar 202011:01 amRNSPrice Monitoring Extension
25th Mar 20207:00 amRNSCOVID-19 Update
19th Mar 20204:15 pmRNSGeneral Meeting: Change of Venue
18th Mar 202011:07 amRNSSecond Price Monitoring Extn
18th Mar 202011:01 amRNSPrice Monitoring Extension
6th Mar 20205:20 pmRNSResult of Placing
6th Mar 20201:20 pmRNSProposed Placing & Open Offer
7th Feb 20207:00 amRNSGrowth & Innovation Forum 2020
4th Feb 20207:00 amRNSSuccessful Stereax Field Trial
23rd Jan 20207:00 amRNSHalf-year Report
15th Jan 202011:06 amRNSSecond Price Monitoring Extn
15th Jan 202011:01 amRNSPrice Monitoring Extension
14th Jan 20204:41 pmRNSSecond Price Monitoring Extn
14th Jan 20204:36 pmRNSPrice Monitoring Extension
13th Jan 202011:08 amRNSSecond Price Monitoring Extn
13th Jan 202011:05 amRNSPrice Monitoring Extension
10th Jan 20202:07 pmRNSSecond Price Monitoring Extn
10th Jan 20202:01 pmRNSPrice Monitoring Extension
2nd Jan 20204:41 pmRNSSecond Price Monitoring Extn
2nd Jan 20204:37 pmRNSPrice Monitoring Extension
19th Dec 20194:56 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.